Johannes Gerardus Chri Schikan Sells 6,888 Shares of Pharvaris (NASDAQ:PHVS) Stock

Posted by Brian Himes on Jul 3rd, 2026

Pharvaris N.V. (NASDAQ:PHVS – Get Free Report) Director Johannes Gerardus Chri Schikan sold 6,888 shares of the firm’s stock in a transaction on Monday, June 29th. The stock was sold at an average price of $35.05, for a total value of $241,424.40. Following the transaction, the director owned 345,879 shares in the company, valued at $12,123,058.95. This trade represents a 1.95% decrease in their ownership of the stock. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website.

Johannes Gerardus Chri Schikan also recently made the following trade(s):

On Tuesday, June 30th, Johannes Gerardus Chri Schikan sold 30,712 shares of Pharvaris stock. The stock was sold at an average price of $35.49, for a total transaction of $1,089,968.88.
On Thursday, April 30th, Johannes Gerardus Chri Schikan sold 29,070 shares of Pharvaris stock. The shares were sold at an average price of $30.32, for a total transaction of $881,402.40.
On Wednesday, April 29th, Johannes Gerardus Chri Schikan sold 3,830 shares of Pharvaris stock. The stock was sold at an average price of $30.07, for a total transaction of $115,168.10.
On Thursday, April 23rd, Johannes Gerardus Chri Schikan sold 100 shares of Pharvaris stock. The stock was sold at an average price of $30.03, for a total transaction of $3,003.00.
On Wednesday, April 22nd, Johannes Gerardus Chri Schikan sold 7,000 shares of Pharvaris stock. The shares were sold at an average price of $30.05, for a total transaction of $210,350.00.

Pharvaris Stock Down 0.3%

Shares of NASDAQ:PHVS opened at $33.86 on Friday. Pharvaris N.V. has a fifty-two week low of $17.05 and a fifty-two week high of $35.90. The firm has a 50-day simple moving average of $31.00 and a 200 day simple moving average of $28.28. The company has a market cap of $2.21 billion, a PE ratio of -10.65 and a beta of -2.34.

Pharvaris (NASDAQ:PHVS – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.70) earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of ($0.82) by $0.12. As a group, research analysts forecast that Pharvaris N.V. will post -3.2 EPS for the current fiscal year.

Institutional Trading of Pharvaris

Institutional investors have recently made changes to their positions in the stock. GF Fund Management CO. LTD. bought a new stake in Pharvaris during the fourth quarter worth approximately $35,000. JPMorgan Chase & Co. boosted its stake in Pharvaris by 30.6% during the 2nd quarter. JPMorgan Chase & Co. now owns 3,342 shares of the company’s stock valued at $59,000 after purchasing an additional 783 shares in the last quarter. Barclays PLC acquired a new position in shares of Pharvaris during the 4th quarter valued at $77,000. Mirae Asset Global Investments Co. Ltd. acquired a new position in shares of Pharvaris during the 4th quarter valued at $86,000. Finally, Zurcher Kantonalbank Zurich Cantonalbank bought a new stake in shares of Pharvaris in the 4th quarter worth $110,000.

Trending Headlines about Pharvaris

Here are the key news stories impacting Pharvaris this week:

Positive Sentiment: Cantor Fitzgerald reaffirmed its Buy rating on Pharvaris, reinforcing a favorable analyst view of the company’s outlook. Cantor Fitzgerald Reaffirms Their Buy Rating on Pharvaris (PHVS)
Positive Sentiment: PHVS recently set a new 1-year high, showing strong momentum and suggesting investors have been optimistic heading into this period. Pharvaris (NASDAQ:PHVS) Sets New 1-Year High – Still a Buy?
Neutral Sentiment: Insider trading activity was heavy over June 29-30, with Director Johannes Gerardus Chri Schikan and insider Anne Lesage selling shares at prices around $35.05-$35.49. The sales may create some concern about near-term sentiment, but they do not necessarily indicate a change in the company’s fundamentals. SEC insider filing

Analyst Upgrades and Downgrades

A number of brokerages recently commented on PHVS. Royal Bank Of Canada lowered their price objective on Pharvaris from $52.00 to $51.00 and set an “outperform” rating for the company in a research note on Monday, April 6th. UBS Group set a $74.00 price target on shares of Pharvaris in a report on Wednesday, May 13th. Wall Street Zen raised shares of Pharvaris from a “sell” rating to a “hold” rating in a report on Saturday, June 6th. Citigroup restated a “buy” rating on shares of Pharvaris in a research report on Wednesday, April 15th. Finally, Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Pharvaris in a report on Tuesday, April 21st. Ten research analysts have rated the stock with a Buy rating, two have issued a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and a consensus target price of $49.64.

Read Our Latest Research Report on PHVS

About Pharvaris

(Get Free Report)

Pharvaris is a clinical-stage biopharmaceutical company focused on discovering and developing novel oral therapies for rare bradykinin-driven diseases. The company’s core mission is to address conditions characterized by uncontrolled activation of the plasma kallikrein-kinin system, with a primary emphasis on hereditary angioedema (HAE), a debilitating disorder marked by recurrent swelling episodes.

The company’s lead program, PHA121, is an investigational once-daily oral plasma kallikrein inhibitor designed for prophylactic treatment of HAE and is advancing through clinical trials.